Shares in US biotech INmune Bio slumped by around 60% following news that its Phase II Alzheimer’s study failed to hit its ...

Despite major strides in antiretroviral therapy (ART), the human immunodeficiency virus (HIV) market still faces serious ...

Clinical-stage oncology company Revolution Medicines and fellow USA-based Summit Therapeutics have entered into a clinical ...

As pressure builds around drug pricing and access, US trade group PhRMA is pushing back against criticism of pharmaceutical ...

The US Food and Drug Administration (FDA) has approved Japanese pharma major Takeda’s Gammagard Liquid ERC [immune globulin ...

Acquisitions in Alzheimer’s drug development have soared, with deal value jumping from $2 billion in 2022 to nearly $18 ...

Japanese drugmaker Shionogi (TYO: 4507) has filed a supplemental application in Japan to broaden the use of its oral ...

US biopharma Alto Neuroscience, a firm focused on the development of novel precision medicines for neuropsychiatric disorders ...

US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus ...

US mRNA specialist Moderna today announced positive results from a Phase III efficacy study (P304) evaluating the relative ...

Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) ...

US pharma major AbbVie is to buy Capstan Therapeutics, a San Diego-based biotech advancing in vivo engineering of cells ...